GPhA has already issued its PR in support of the bill (#msg-17057467). BIO will presumably come out with a PR in opposition, but this time I think they’re fighting a losing battle.
Waxman had a busy couple of days. First he denounced NVS for trying to enforce its patents against Indian generic Gleevec competition. Now he introduces legislation for generic biopharma drugs. Looks like he comes down squarely on the side of cheaper drugs regardless of whether it violates intellectual property rights or not.
Anyone know the specifics on how the legislation proposes bioequivalency should be demonstrated?
News 
Market Data 
Discover 
AI
